

Datasheet: PIP012

BATCH NUMBER 147479

Description:	NATIVE INFLUENZA B ANTIGEN
Name:	INFLUENZA B ANTIGEN
Format:	Inactivated Pathogen
Product Type:	Antigen
Quantity:	1 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Viral
Product Form	Inactivated Influenza B antigen - liquid
Preparation	Influenza B, strain Hong Kong 5/72, cultured in MDCK cells. Clarified and concentrated cell culture supernatant. The antigen preparation is inactivated by gamma radiation.
Buffer Solution	Eagle's Minimum Essential Medium
Preservative Stabilisers	None present
Approx. Protein Concentrations	Total protein concentration 1.70 mg/ml

Product Information

This product is a native influenza B antigen. Influenza is an acute infection of the respiratory tract caused by the Influenza virus, of which there are several different types.

Influenza B is only known to infect humans and seals. Influenza infection in humans causes chills, fever, pharyngitis, muscle pain, headaches, coughing and weakness. The

virus is transmitted through the air by coughs or sneezes or through saliva, nasal secretions, faeces and blood. Infection may occur through direct contact with infected bodily fluid or contaminated surfaces. Influenza B viruses mutate slower than Influenza A, but fast enough that lasting immunity is not possible. The slower mutation rate and limited host range makes Influenza B less like to cause pandemics than Influenza A.

Activity	20480 HA units/ml as determined by hemagglutination endpoint assay.
-----------------	---

Instructions For Use	The preparation might be slightly cloudy or contain minor precipitate upon thawing. Do not sonicate and do not clarify prior to dilution at least 10-fold with working buffer.
-----------------------------	--

Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.
----------------	--

Guarantee	18 months from date of despatch
------------------	---------------------------------

Health And Safety Information	Material Safety Datasheet documentation #10286 available at: https://www.bio-rad-antibodies.com/SDS/PIP012 10286 This product has been rendered inactive by gamma radiation. However this material should still be handled as infectious and should be disposed of appropriately.
--------------------------------------	--

Regulatory	For research purposes only
-------------------	----------------------------

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M359465:190916'

Printed on 07 Nov 2024